Pharmacokinetics of nimesulide

Nimesulide - Actions and Uses

Volumn , Issue , 2005, Pages 63-120

  Bernareggi, A ^a   Rainsford, K D ^b  

^a Cell Therapeutics Europe   (Italy)

^b SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33745694193     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-7643-7410-1_2     Document Type: Chapter

References (87)

1. Davis R, Brogden RN (1994) Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 48:431-454
2. Bernareggi A (1993) The pharmacokinetic profile of nimesulide in healthy volunteers. Drugs 46(Suppl. 1):64-72
3. Bernareggi A (1998) Clinical pharmacokinetics of nimesulide. Clinical Pharmacokinetics 35:247-274
4. Olive G, Rey E (1993) Effect of age and disease on the pharmacokinetics of nimesulide. Drugs 46(Suppl. 1):73-78
5. Bernareggi A (2001) Clinical pharmacokinetics and metabolism of nimesulide. Inflammopharmacology 9:81-89
6. Regazzoni S (2001) Coefficienti di permeabilità apparente tramite la camera di Ussing e assorbimento di farmaci nell'uomo. Thesis, Milan: Faculty of Pharmacy, University of Milan, Italy
7. Bugatti C, Livi V (2000) Nimesulide: determination of aqueous solubility and logP. Helsinn Healthcare, data on file
8. Löbenberg R, Amidon GL (2000) Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharmaceut Biopharm 50:3-12
9. Rainsford KD (1999) Profile and mechanism of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 107:27S-36S
10. McCormack K, Brune K (1987) Classical absorption theory and the development of gastric mucosal damage associated with the non-steroidal anti-inflammatory drugs. Arch Toxicol 60:261-269
11. Casciarri I, Bernareggi A (1991) Disposition of total radioactivity and plasma levels of nimesulide and OH-nimesulide in rats after intravenous and oral administration. Helsinn Healthcare, data on file
12. McGeer PL, Schulzer M, McGeer EG (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology 47:425-432
13. Pasinetti GM (1999) US patent No. 5, 985, 930, Treatment of neurodegenerative conditions with nimesulide
14. Boje K M K, Jaworowicz Jr D, Raybon JJ (2003) Neuroinflammatory role of prostaglandins during experimental meningitis: Evidence suggestive of an in vivo relationship between nitric oxide and prostaglandins. Pharmacol Exper Therap 304:319-325
15. Gupta SK, Bhardwaj RK, Tyagi P, Sengupta S, Velpandian T (1999) Anti-inflammatory activity and pharmacokinetic profile of a new parenteral formulation of nimesulide. Pharmacol Res 39:138-141
16. Toutain PL, Cester CC, Haak T, Metge S (2001) Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. J Vet Pharmacol Therap 24:35-42
17. Toutain PL, Cester CC, Haake T, Laroute V (2001) A pharmacokinetic/pharmacodynamic approach vs. a dose titration for the determination of a dosage regimen: the case of nimesulide, a COX-2 selective nonsteroidal anti-inflammatory in the dog. J Vet Pharmacol Therap 24:43-55
18. Castoldi D, Monzani V, Tofanetti O (1988) Simultaneous determination of nimesulide and hydroxynimesulide in human plasma and urine by high-performance liquid chromatography. J Chromat B 425:413-418
19. Bernareggi A, Castoldi D, Nava ML, Ratti E (1998) Linear pharmacokinetics of oral nimesulide in healthy male volunteers treated with 25, 50 and 100 mg. Helsinn Healthcare, data on file
20. Remuzzi G, Gaspari F, Taiocchi L (1991) Development of micromethods to study the pharmacokinetic profile for brodimoprim and nimesulide in small volumes of biological fluids. Helsinn Healthcare, data on file
21. Giachetti C, Tenconi A (1998) Determination of nimesulide and hydroxynimesulide in human plasma by high performance liquid chromatography. Biomed Chromatogr 12:50-56
22. Abbiati G, Rigoldi M, Parisi S, Arrigoni M (1996) Farmacocinetica e biodisponibilità di nimesulide beta-ciclodestrina granulato nel volontario sano. Giorn Ital Ric Clin Terap 17:1-4
23. Lücker PW (1992) Study on the pharmacokinetics (food/drug interaction) and relative bioavailability of three different treatments with nimesulide in 18 healthy male volunteers. Helsinn Healthcare, data on file. TSD No. 5565E
24. Lücker PW (1991) Report on the pharmacokinetics and relative bioavailability/bioequivalence of three different nimesulide formulations in 18 healthy male volunteers. Helsinn Healthcare, data on file. TSD No. 5356E
25. Alessandrini A, Ballarin E, Bastianon A, Migliavacca C (1986) Confronto di biodisponibilità tra due diverse forme farmaceutiche orali equidosate di nimesulide in volontari sani. Clinica Terapeutica 118:177-182
26. Scheen A (1997) Open, randomized, crossover, bioequivalence study of three different formulations of nimesulide, after single oral dose administration in 24 healthy subjects. Helsinn Healthcare, data on file. TSD No. 7215E
27. Lücker PW (1993) Report of the study on the pharmacokinetics of nimesulide and its main metabolite 4-OH-nimesulide after oral administration of three different doses in healthy male volunteers. Helsinn Healthcare, data on file. TSD No. 5781E
28. ®) in somministrazione singola e ripetuta. Helsinn Healthcare, data on file. TSD No. 5437E
29. Bernasconi PC (1989 Pharmacokinetics of nimesulide: relative bioavailability of the rectal versus the oral administration. A single and repeated dose study in healthy volunteers. Helsinn Healthcare, data on file. TSD No. 5252E
30. Gandini R, Montalto C, Castoldi D, Monzani V, Nava ML, Scaricabarozzi I, Vargiu G, Bartosek I (1991) First dose and steady-state pharmacokinetics of nimesulide and its 4-hydroxy metabolite in healthy volunteers. Farmaco 46:1061-1079
31. Ugazio AG, Guarnaccia S, Berardi M, Renzetti I (1993) Clinical and pharmacokinetic study of nimesulide in children. Drugs 46(Suppl. 1):215-218
32. Pulkkinen M (1993) Nimesulide in dysmenorrhoea. Drugs 46(Suppl. 1):129-133
33. Diamond G (1976) Standard dossier - Volume 2 - pp 181-210. Single dose study using R805-14C. Helsinn Healthcare, data on file. TSD No. 3007E
34. Allemon AM, Lebacq E (1993) Study of the excretion balance and metabolism of [14C] nimesulide after single oral dose administration in 6 healthy male volunteers. Helsinn Healthcare, data on file. TSD No. 5755E
35. McCracken NW, Sanderson BJ, Young CG (1997) The excretion and plasma kinetics of [14C] nimesulide in man following a single oral administration. Helsinn Healthcare, data on file. TSD No. 7277E
36. Macpherson D, Best SA, Gedik L, Hewson AT, Rainsford KD, Parisi F (2004) The biotransformation and pharmacokinetics in humans of single dose of 14C-nimesulide. Helsinn Healthcare, data on file
37. Brambilla A, Maffei Facino R (1989) Metabolismo del farmaco antiinfiammatorio nimesulide nell'uomo. Thesis, Milan: Faculty of Pharmacy, University of Milan, Italy
38. Maffei Facino R, Carini M, Stefani R, Marinello C (1997) In vitro metabolism of the antiinflammatory drug nimesulide in man: simultaneous determination of the main urinary metabolites by HPLC with UV-DAD detection. Proceedings of the 7th meeting on Recent developments in Pharmaceutical Analysis (RDPA'97), Sept. 16-22, 1997, Isola d'Elba, p. 28
39. Castoldi D (1989) Escrezione urinaria della nimesulide dopo somministrazione unica al volontario sano. Helsinn Healthcare, data on file
40. Davis SS, Hardy JG, Fara JW (1986). Transit of pharmaceutical dosage forms through the small intestine. Gut 27:886-892
41. ® capsule in healthy volunteers, Helsinn Healthcare, data on file
42. Gardner D, Casper R, Leith F, Wilding I (1997) Non-invasive methodology for assessing regional drug absorption from the gastrointestinal tract. Pharm Tech Europe 203
43. Lin JH, Cocchetto DM, Duggan DE (1987) Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 12:402-432
44. Verbeeck RK (1990) Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 19:44-66
45. Brouwers J, De Smet P (1994) Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 27:462-485
46. Graham GG, Champion GD, Day RO, Paull PD (1977) Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis. Clin Pharmacol Ther 22:410-420
47. Davies NM, Anderson KE (1977) Clinical pharmacokinetics of diclofenac. Clin Pharmacokinet 33:184-213
48. Davies NM (1995) Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet 28:100-114
49. Davies NM (1996) Clinical pharmacokinetics of tiaprofenic acid and its enantiomers. Clin Pharmacokinet 31:331-347
50. Davies NM, Anderson KE (1997) Clinical pharmacokinetics of naproxen. Clin Pharmacokinet 32:268-293
51. Pulkkinen MO, Vuento M, Macciocchi A., Monti T (1991). Distribution of oral nimesulide in female genital tissues. Biopharm Drug Disp 12:113-117
52. Lignière GC, Tamborini U, Panarace G, Abbiati G, Montagnani G (1990) La nimesulide nel liquido sinoviale di paziente con artrite reumatoide. Farmaci e Terapia 7:173-176
53. Vilageliu J (1983) Nimesulide evaluation of protein binding and the effects of possible displacers. Helsinn Healthcare, data on file. TSD No. 3545E
54. Bree F, Nguyen P, Urien S, Albengres E, Macciocchi A, Tillement JP (1993) Nimesulide binding to components within blood. Drugs 46(Suppl. 1):83-90
55. Milvio I (1984) Confronto di biodisponibilità tra due diversi lotti con massa witepsol. Helsinn Healthcare, data on file. TSD No. 4038
56. Maffei Facino R, Carini M, Brambilla A, Casciarri I, Scaricabarozzi I, Tofanetti O (1989) Metabolism of nimesulide in man and radical scavenging activity of its main metabolites. 3rd Interscience World Conference on Antirheumatics, Analgesics, Immunomodulators, Montecarlo, March 15-18, 1989. Abstract Book p. 244
57. Carini M, Aldini G, Stefani R, Marinello C and Facino RM (1998) Mass spectometric characterisation and HPLC determination of the main urinary metabolites of nimesulide in man. J Pharm Biomed Anal 18:201-211
58. Ogaki J (1999) Studies on the regulational activities of NIM-03 on human liver microsomal CYP isozymes. Helsinn Healthcare, data on file
59. Rainsford KD (2004) Pharmacology and toxicology of COX-2 inhibitors. In: Pairet M, van Ryn J (eds): COX-2 inhibition. Birkhäuser Verlag, Basel, 67-131
60. Maffei Facino R, Carini M, Aldini G (1993) Antioxidant activity of nimesulide and its main metabolites. Drugs 46(Suppl. 1):15-21
61. Pirovano R (1988) Study of the capacity of the test article BBR 2335/7 to induce gene mutations in strains of Salmonella typhimurium. Helsinn Healthcare, data on file
62. Pirovano R (1989) Study of the capacity of the test article BBR 2395 to induce gene mutations in strains of Salmonella typhimurium. Helsinn Healthcare, data on file
63. Brodie B, Lowman E, Burns J, Lee P, Chenkin T et al. (1954) Observations on the antirheumatic and physiologic effects of phenylbutazone and some comparisons with cortisone. Am J Med 16:181-190
64. Runkel R, Forchielli E, Sevelius H, Chaplin M, Segre E (1974) Nonlinear plasma level response to high doses of naproxen. Clin Pharmacol Ther 15:261-266
65. Lin JH, Hooke KF, Yeh KC, Duggan DE (1985) Dose-dependent pharmacokinetics of diflunisal in rats: dual effects of protein binding and metabolism. J Pharmacol Exp Ther 235:402-406
66. Schärli AF, Brülhart K, Monti T (1990) Pharmacokinetics and therapeutic study with nimesulide suppositories in children with post-operative pain and inflammation. J Int Med Res 18:315-321
67. Gupta SK, Prakash J, Awor L, Joshi S, Velpandian T, Sengupta S (1996) Anti-inflammatory activity of topical nimesulide gel in various experimental models. Inflamm Res 45:590-592
68. Menegatti E (1996) In vitro permeability test on different formulations. Helsinn Healthcare, Report No. TSD 7565E
69. Berardesca E (1998) Evaluation of skin irritation and sensitization potential of different nimesulide topical formulations by repeated insult patch test in healthy volunteers. Helsinn Healthcare, Report No. TSD 6103
70. Thompson CA, Dennis G (1997) A comparative kinetic study of nimesulide following administration of an oral formulation and a topical formulation to 18 healthy male volunteers. Helsinn Healthcare, Report No. TSD 7224 E
71. Eichler HG (1999) Pharmacokinetics profile and transdermal penetration of nimesulide in male, healthy volunteers after single and multiple epicutaneous administration of a new 3% gel formulation. Helsinn Healthcare, Report No. TSD 7781 2 E
72. Babu RJ, Kanikkanun N, Kikwai L, Ortega C, Andega S, Ball K, Yim S, Singh M (2003) The influence of various methods of cold storage of skin on the permeation of melatonin and nimesulide. J Controlled Rel 86:49-57
73. Lücker PW (1992) Study on the pharmacokinetics (single and multiple dose) of nimesulide in 10 elderly subjects. Helsinn Healthcare, Report No. TSD 5619E
74. Pontiroli AE (1991) Report on the pharmacokinetics of nimesulide in elderly patients with normal and elevated creatinine plasma concentrations after single and repeated doses. Helsinn Healthcare, Report No. TSD 5520E
75. Mosteller RD (1987) Simplified calculation of body surface area. New Engl J Med 317(17):1098
76. Fillastre JP (1991) Pharmacokinetics of nimesulide after single oral dose in patients with moderate renal insufficiency. Helsinn Healthcare, Report No. TSD 4871E
77. Fouarge M (1992) Pharmacokinetic profile of nimesulide and its OH-metabolite in plasma and urine in 10 subjects with moderate renal failure during repeated oral administration. Helsinn Healthcare, Report No. TSD 5611E
78. Olive G (1993) Pharmacokinetics of nimesulide after single oral administration to healthy subjects and those with hepatic insufficiency. Helsinn Healthcare, Report No. TSD 5498E
79. Perucca E (1993) Drug interactions with nimesulide. Drugs 46(Suppl. 1):79-82
80. Fouarge M (1993) Pharmacokinetic interaction study between nimesulide and glibenclamide after single dose cross-over administration in 12 healthy subjects. Helsinn Healthcare, Report No. TSD 5687E
81. Ugazio G (1993) Pharmacokinetic interaction study between nimesulide tablets and cimetidine tablets after single dose administration to 12 healthy volunteers. Helsinn Healthcare, Report No. TSD 5691E
82. Ugazio G (1993) Pharmacokinetic interaction study between nimesulide tablets and Maalox suspension after single dose administration to 12 healthy volunteers. Helsinn Healthcare, Report No. TSD 5692E
83. Steinhauslin F, Munafo A, Buclin T, Macciocchi A (1993) Renal effects of nimesulide in furosemide-treated subjects. Drugs 46(Suppl. 1):257-262
84. Auteri A, Bruni F, Pasqui AL, Saletti M, Di Renzo M, Blardi P, Domini L, Verzuri S, Di Perri T (1991) Pharmacokinetics and pharmacodynamics of slow-release theophylline during treatment with nimesulide. Int J Clin Pharmacol Res 11:211-218
85. Lücker PW (1993) Report of the study on the possible drug-drug interaction of warfarin and nimesulide in 12 healthy male volunteers. Helsinn Healthcare, Report No. TSD 5686E
86. Baggio E, Maraffi F, Montalto C, Nava ML, Torti L, Casciarri I (1993) A clinical assessment of the potential for pharmacological interaction between nimesulide and digoxin in patients with heart failure. Drugs 46(Suppl. 1):91-94
87. Rainsford KD, Omar H, Ashaf A, Hewson AT, Bunning R A D, Rishiraj R, Shepherd P, Seabrook RW (2002) Recent pharmacodynamic and pharmacokinetic findings on oxaprozin. Inflammopharmacology 10:185-239